Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06479863 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Sporadic Inclusion Body Myositis (sIBM)
Idiopathic Inflammatory Myopathies

Interventions

COMBINATION_PRODUCT: Pozelimab/Cemdisiran

Sponsor

Austin Neuromuscular Center

Collaborators

[object Object]